# PCI BIOTECH

Unlocking the potential of innovative medicines

**BIOEurope Spring 2016** STOCKHOLM, APRIL 5, 2016 Per Walday, CEO

the states and a



### **PCI BIOTECH**

### Important notice and disclaimer

This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on PCI Biotech's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "programmes", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of PCI Biotech's strategy and its ability to further grow, risks associated with the development and/or approval of PCI Biotech's products candidates, ongoing clinical trials and expected trial results, the ability to commercialise fimaporfin (Amphinex®), technology changes and new products in PC Biotech's potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

No assurance can be given that such expectations will prove to have been correct. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



## PCI BIOTECH AT A GLANCE

### Unlocking the potential of innovative medicines

- A listed (PCIB:NO) cancer-focused biotech company
- Photochemical internalisation ("PCI") technology, originating from the Norwegian Radium Hospital

#### Clinical program

**fima** *CHEM* – Phase I/II with fimaporfin (Amphinex<sup>®</sup>) for the orphan indication inoperable bile duct cancer

Pre-clinical programs

**fime VACC** – Vaccination technology that provides strongly enhanced T-cell responses


fima NAc – Efficient intracellular delivery of nucleic acid therapeutics



Bile duct cancer study with promising early signs of efficacy in Phase I and Phase II about to start



Proprietary vaccination technology moving towards clinical validation, and one active research collaboration



Preclinical program with two active research collaborations, one with top tier pharma



## PHOTOCHEMICAL INTERNALISATION

Triggered endosomal release through illumination

#### STEP 1:

• Fimaporfin (S) and the active molecule (D) are injected into the body and reaches the target cells

#### STEP 2:

- Fimaporfin (S) and the active molecule (D) are taken up by the cell, but D is unable to reach the target (T), as it is encapsulated in an endosome
- S is washed away from the cell membrane, but trapped in endosomes

#### STEP 3:

- Light activates fimaporfin (S) in the membrane of the endosome
- · The membrane integrity is affected and the active molecule released

#### STEP 4:

• The active molecule (D) can now bind to its target (T) and initiate the therapeutic response












#### The active molecule

- Anticancer agent, e.g. bleomycin, gemcitabine
- Oligonucleotide, e.g. siRNA
- Protein, e.g. antibody-drug conjugate
- Peptide: e.g. antigen



#### The PCI component

- Light sensitive component
- Fimaporfin Amphinex®




\_

- The target
- Target for the active molecule
- E.g. DNA, mRNA, enzyme, microtubuli



## CLINICAL TECHNOLOGY VALIDATION

Phase I of fimaporfin – combined with bleomycin in recurrent/metastatic cancer



Baseline

Day 28


Day 90

- Very promising early signs of tumour response across a range of fimaporfin dose levels
- Apparent strong selectivity for cancer in several patients
- Well tolerated with appropriate pain control and anaesthesia



### CHEMOTHERAPEUTICS

► A cornerstone in current cancer therapy




- **fima** *CHEM* may enable approved drugs to fulfil unmet local treatment needs
- Aim is to complete Phase II in cholangiocarcinoma before out-licensing
- Opportunity for development in further niche indications



## BILE DUCT CANCER

A rare but fatal disease



- ► Five year survival less than 5%
- Remarkable resistance to chemotherapy
- Estimated market potential of up to USD 500m for efficacious treatment
- Phase I/II trial ongoing with fimaprofin
  - combination with gemcitabine
  - open-label, multi-center trial in up to 45 patients
  - activation of fimaporfin by intraluminal illumination



### BILE DUCT CANCER

Progressing into Phase II with promising early signs of efficacy

#### Why target bile duct cancer?

- Significant inoperable patient population with high unmet local treatment need
- No approved medical treatments
- Limited development pipeline
- Active chemotherapy enhanced by PCI
- Easy access with light through routine endoscopic methods

Attractive due to orphan benefits and absence of satisfying treatments

#### **Current status and plans**

- Safety driven European Phase Ib completed
- Fourth dose cohort concluded Jan 2016 no safety concerns
- Promising early signs of efficacy in third dose cohort – awaiting fourth dose cohort results
- Progressing into Phase II
- Increasing number of sites
- Opening of IND and including US sites
- Obtain orphan designation



## BILE DUCT CANCER – CLINICAL PHASE I/II STUDY

Preliminary response data

### ▶ 6 months radiology (CT) data from 3 dose cohorts

	PD	SD	PR	CR	NA*
Cohort 1	1	1			1
Cohort 2		1			2**
Cohort 3		1	1	1	
Cohort 4	Not yet available – subjects on-going				

\* Not measurable / Not evaluable by CT


\*\* Considered SD at 6 months by the investigator

- Subjects are in the study for 6 months after PCI treatment
- Dose levels given in cohort 1 and 2 are below what is expected to be effective from previous clinical experience



### MMUNOTHERAPY

A new hope for millions of patients




- **fime** *Vacc* enhances cellular immune responses important for therapeutic effects
- Moving towards clinical validation, potentially in healthy volunteers
- Aim is to out-license the technology on non-/semi-exclusive basis
- Opportunity to develop own therapeutic vaccination products



### PCI FOR VACCINATION


Enhancing cytotoxic T-cell response by light-induced cross presentation




### THERAPEUTIC VACCINATION

► In vivo immunisation with HPV long peptide

fima VACC strongly enhance CD8 T-cell response and induces strong anti-tumour response






- Intradermal vaccination at days 6 and 13 after tumour cell inoculation
- 5 animals per group




## SYNERGY WITH OTHER TECHNOLOGIES

Acts synergistically with other vaccination enhancement technologies

- Acts synergistically with several commonly used vaccine adjuvants
- Works with many different peptide antigens and stimulates both CTL proliferation and IFN-γ production







## THERAPEUTIC VACCINATION WITH **fima** VACC

Opportunity to play a key role in second generation immunotherapy



#### Unique mode of action

- indication of CTL-induction by MHC class I antigen presentation in dendritic cells and macrophages
- Broad applicability
  - peptide and protein antigens
  - particulate antigen formulations
  - prophylactic & therapeutic vaccination
- Safety of fimaporfin confirmed in Phase I studies
- Excellent stability
  - stable at room temperature
  - stable in solution
  - can be autoclaved
- Cost effective synthesis



### fima*NAc*

## NUCLEIC ACID THERAPEUTICS

A treatment modality with huge potential



- ▶ fima NAc may provide a delivery solution for many nucleic acid therapy applications
- Opportunistic collaborative approach
- Aim is to out-license the technology on non-/semi-exclusive basis




### fima*NAc*

### ENHANCING MRNA DELIVERY

Strongly increased GFP synthesis with increasing light doses

fima NAc with polyethylenimine vehicle



16

## **Research Collaborations**

Three active collaborations within nucleic acid therapeutics and vaccination

#### Top-10 large pharma company

- Agreement signed in 3Q 2015
- Evaluate synergistic effects between companies' technologies
- One of the global leaders in nucleic acid therapeutics
- Collaborative research funded and initiated
- Data generated in research collaboration to be evaluatedpotential for a further partnership

#### **RXi Pharmaceuticals**

- Agreement signed 2Q 2015
- RXi Pharmaceuticals listed on Nasdaq (NASDAQ: RXII)
- Discovers and develops innovative therapeutics within dermatology and ophthalmology
- Results achieved from this research collaboration to be evaluatedpotential for closer collaboration

### <u>Ultimovacs</u>



- Agreement signed 1Q 2016
- Ultimovacs AS, Norwegian
  immunotherapy company
- Developing UV1, a therapeutic cancer vaccine directed against human telomerase
- Results from this research collaboration to be evaluatedpotential for closer collaboration



## KEY MILESTONES THROUGH 2018

Unlocking the true potential of innovative medicine

